Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
$2.68
-3.9%
$2.89
$1.61
$4.00
$39.60M0.4724,923 shs1,105 shs
Calyxt, Inc. stock logo
CLXT
Calyxt
$6.30
$13.58
$1.25
$7.77
$31.31M1.98139,308 shs254,056 shs
LianBio stock logo
LIAN
LianBio
$0.33
+6.4%
$0.31
$0.27
$4.99
$35.88M0.231.04 million shs127,869 shs
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
$1.67
-5.1%
$1.81
$1.50
$4.58
$45.63M0.39170,506 shs320,782 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
-4.06%-8.33%-13.09%-4.74%+1.78%
Calyxt, Inc. stock logo
CLXT
Calyxt
0.00%0.00%0.00%0.00%-76.62%
LianBio stock logo
LIAN
LianBio
0.00%+6.00%+18.23%-93.11%-86.39%
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
-5.11%-3.47%+3.73%-35.52%-57.07%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
0.0492 of 5 stars
0.02.00.00.00.01.70.6
Calyxt, Inc. stock logo
CLXT
Calyxt
N/AN/AN/AN/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/AN/AN/AN/A
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
2.4956 of 5 stars
3.61.00.00.03.71.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
N/AN/AN/AN/A
Calyxt, Inc. stock logo
CLXT
Calyxt
N/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
2.00
Hold$5.331,506.43% Upside
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
3.20
Buy$18.751,022.75% Upside

Current Analyst Ratings

Latest CLXT, LIAN, OCUP, and CGA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2024
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2024
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $18.00
5/13/2024
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/20/2024
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $20.00
(Data available from 5/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
$99.88M0.40N/AN/A$9.37 per share0.29
Calyxt, Inc. stock logo
CLXT
Calyxt
$160K195.69N/AN/A$0.54 per share11.67
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
$19.05M2.27N/AN/A$1.78 per share0.94

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
-$13.28M-$2.02N/AN/A-27.43%-22.74%-15.03%11/1/2024 (Estimated)
Calyxt, Inc. stock logo
CLXT
Calyxt
-$16.89M-$3.49N/AN/AN/A-9,979.64%-259.69%-83.22%N/A
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
-$9.99M-$0.49N/AN/AN/A-59.44%-24.57%-22.22%8/9/2024 (Estimated)

Latest CLXT, LIAN, OCUP, and CGA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/8/2024Q4 2023
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
-$0.07-$0.21-$0.14-$0.21$3.47 million$1.69 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
$0.103.74%N/AN/A N/A
Calyxt, Inc. stock logo
CLXT
Calyxt
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
N/A
2.22
1.62
Calyxt, Inc. stock logo
CLXT
Calyxt
N/A
0.61
0.61
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/A
8.96
8.96

Ownership

Institutional Ownership

CompanyInstitutional Ownership
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
0.12%
Calyxt, Inc. stock logo
CLXT
Calyxt
6.77%
LianBio stock logo
LIAN
LianBio
74.85%
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
14.97%

Insider Ownership

CompanyInsider Ownership
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
34.25%
Calyxt, Inc. stock logo
CLXT
Calyxt
2.20%
LianBio stock logo
LIAN
LianBio
7.59%
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
8.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
China Green Agriculture, Inc. stock logo
CGA
China Green Agriculture
60014.79 million9.73 millionOptionable
Calyxt, Inc. stock logo
CLXT
Calyxt
484.97 million4.87 millionNot Optionable
LianBio stock logo
LIAN
LianBio
163108.06 million99.86 millionNot Optionable
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
1425.92 million23.67 millionOptionable

CLXT, LIAN, OCUP, and CGA Headlines

Recent News About These Companies

Ocuphire Pharma, Inc. (OCUP)
First patient enrolled in LYNX-2 Phase 3 study
Viatris launches Ryzumvi in USA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

China Green Agriculture logo

China Green Agriculture

NYSE:CGA
China Green Agriculture, Inc., through its subsidiaries, engages in the research, development, production, and sale of various fertilizers, agricultural products, and bitcoin in the People's Republic of China and the United States. The company operates through four segments: Jinong (Fertilizer Production); Gufeng (Fertilizer Production); Yuxing (Agricultural Products Production); and Antaeus (Bitcoin). It offers humic acid-based compound, blended, organic compound, slow-release, compound, highly concentrated water-soluble, and mixed organic-inorganic compound fertilizers, as well as develops, produces, and distributes agricultural products, such as fruits, vegetables, flowers, and colored seedlings. The company also produces and sells bitcoins. The company also markets its fertilizer products to private wholesalers and retailers of agricultural farm products. The company sells its decorative flowers to end-users, such as flower shops, luxury hotels, and government agencies; fruits and vegetables to supermarkets and upscale restaurants; and seedlings to city planning departments. As of June 30, 2023, the company operated a network of 1,328 distributors covering 22 provinces, 4 autonomous regions, and 4 central government-controlled municipalities in China. The company also exports its products through contracted distributors to various countries, including India and Africa. China Green Agriculture, Inc. was incorporated in 1987 and is based in Xi'an, the People's Republic of China.
Calyxt logo

Calyxt

NASDAQ:CLXT
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company to enhance the quality of alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota.
LianBio logo

LianBio

NASDAQ:LIAN
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Ocuphire Pharma logo

Ocuphire Pharma

NASDAQ:OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.